Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

61.74
+0.40000.65%
Post-market: 61.740.00000.00%19:05 EDT
Volume:628.86K
Turnover:38.70M
Market Cap:3.90B
PE:-14.23
High:61.96
Open:61.11
Low:60.93
Close:61.34
Loading ...

Rhythm Pharmaceuticals: MHRA expands marketing authorization for Imcivree

TIPRANKS
·
03 Dec 2024

Rhythm Pharmaceuticals Inc - Imcivree Expected to Be Available by Year-End Through Medicines for Children Program

THOMSON REUTERS
·
03 Dec 2024

Rhythm Pharmaceuticals Announces ▼ Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients With Bardet Biedl Syndrome or Pomc, Pcsk1, or Lepr Deficiency to Include Children as Young as 2 Years Old

THOMSON REUTERS
·
03 Dec 2024

Fintech Approaches Buy Point Of Extremely Rare Pattern Following 44% Burst

Blockhead
·
27 Nov 2024

Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge

Blockhead
·
26 Nov 2024

Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Nov 2024

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level

Blockhead
·
19 Nov 2024

TD Cowen Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
19 Nov 2024

Rhythm Pharmaceuticals announces five presentations at ESPE 2024

TIPRANKS
·
18 Nov 2024

Rhythm Pharmaceuticals Announces Five Presentations at Espe 2024, Including New Real-World Data in Pediatric Patients With Acquired or Congenital Hypothalamic Obesity Treated With Setmelanotide

THOMSON REUTERS
·
18 Nov 2024

Rhythm Pharmaceuticals Inc - to Enroll First Patients in Congenital Hypothalamic Obesity Study in Q1 2025

THOMSON REUTERS
·
18 Nov 2024

Rhythm announces publication of setmelanotide Phase 3 results in The Lancet

TIPRANKS
·
14 Nov 2024

Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
07 Nov 2024

Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
07 Nov 2024

Rhythm Pharmaceuticals’ Common Stock Faces Risks from Convertible Preferred Stock Supremacy

TIPRANKS
·
07 Nov 2024

Stock Track | Rhythm Pharma Soars 14% After Smashing Q3 Earnings Expectations

Stock Track
·
06 Nov 2024

Stock Track | Rhythm Pharma Soars 14% Pre-Market on Strong Q3 Earnings Beat

Stock Track
·
06 Nov 2024

Rhythm Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
06 Nov 2024

Rhythm Pharmaceuticals Inc : TD Cowen Raises Target Price to $65 From $55

THOMSON REUTERS
·
06 Nov 2024

Rhythm Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary

Reuters
·
06 Nov 2024